APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemocompatible Coatings

Hemocompatible coatings constitute advanced interfacial modifications applied to the surfaces of blood-contacting medical devices to mitigate the risk of thrombosis and associated complications. These coatings function by attenuating the initial adsorption of plasma proteins, particularly fibrinogen and von Willebrand factor, thereby suppressing subsequent platelet adhesion, activation, and aggregation, as well as inhibiting activation of the intrinsic coagulation pathway. Effective hemocompatibility is achieved through precise control of surface chemistry and topography, addressing the fundamental challenge that virtually all synthetic biomaterials elicit a thrombogenic response upon blood exposure unless appropriately engineered.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hemocompatible coatings constitute advanced interfacial modifications applied to the surfaces of blood-contacting medical devices to mitigate the risk of thrombosis and associated complications. These coatings function by attenuating the initial adsorption of plasma proteins, particularly fibrinogen and von Willebrand factor, thereby suppressing subsequent platelet adhesion, activation, and aggregation, as well as inhibiting activation of the intrinsic coagulation pathway. Effective hemocompatibility is achieved through precise control of surface chemistry and topography, addressing the fundamental challenge that virtually all synthetic biomaterials elicit a thrombogenic response upon blood exposure unless appropriately engineered.

Classification of hemocompatible coatings is based primarily on mechanism: active bioactive coatings versus passive bioinert coatings. Active coatings utilize covalently immobilized anticoagulants, with endpoint-attached heparin being the predominant example; the preserved antithrombin-binding pentasaccharide sequence catalyzes the inhibition of thrombin and factor Xa at the device surface without elution of the heparin molecule. Passive coatings rely on biomimetic or highly hydrophilic polymers, notably phosphorylcholine-based methacrylates, which replicate the zwitterionic character of the outer leaflet of endothelial cell membranes to form a stable hydration shell. This layer exerts steric repulsion and charge neutrality to minimize nonspecific protein fouling and cellular interactions independent of any pharmacological activity.

Deposition methods encompass covalent photoimmobilization, endpoint chemical coupling, plasma polymerization, and solution-based coating techniques, each optimized for substrate compatibility and mechanical durability under physiological shear stress. These technologies are integrated into a broad spectrum of devices, encompassing coronary and peripheral endovascular stents, ePTFE and polyester vascular grafts, indwelling catheters for central venous access and hemodialysis, extracorporeal membrane oxygenation circuits and cardiopulmonary bypass components, and rotary blood pumps in ventricular assist systems. Validation through ISO 10993-4 hemocompatibility testing protocols, complemented by ex vivo flow loop studies, large-animal implantation models, and clinical performance data from regulatory-approved devices, substantiates the reduction in thrombus formation and improvement in device patency and safety.

Selected research

Market Analysis & Forecast

Global Hemocompatible Coatings Market Analysis and Forecast 2026-2032

3 August 2026177 pages

Choose your research edition.

Industry ResearchHemocompatible Coatings Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemocompatible Coatings Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Hemocompatible Coatings Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemocompatible Coatings Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemocompatible Coatings Market Analysis and Forecast 2026-2032177 pages · $4,950 USD

Market perspective

Hemocompatible coatings constitute advanced interfacial modifications applied to the surfaces of blood-contacting medical devices to mitigate the risk of thrombosis and associated complications. These coatings function by attenuating the initial adsorption of plasma proteins, particularly fibrinogen and von Willebrand factor, thereby suppressing subsequent platelet adhesion, activation, and aggregation, as well as inhibiting activation of the intrinsic coagulation pathway. Effective hemocompatibility is achieved through precise control of surface chemistry and topography, addressing the fundamental challenge that virtually all synthetic biomaterials elicit a thrombogenic response upon blood exposure unless appropriately engineered.

Classification of hemocompatible coatings is based primarily on mechanism: active bioactive coatings versus passive bioinert coatings. Active coatings utilize covalently immobilized anticoagulants, with endpoint-attached heparin being the predominant example; the preserved antithrombin-binding pentasaccharide sequence catalyzes the inhibition of thrombin and factor Xa at the device surface without elution of the heparin molecule. Passive coatings rely on biomimetic or highly hydrophilic polymers, notably phosphorylcholine-based methacrylates, which replicate the zwitterionic character of the outer leaflet of endothelial cell membranes to form a stable hydration shell. This layer exerts steric repulsion and charge neutrality to minimize nonspecific protein fouling and cellular interactions independent of any pharmacological activity.

Deposition methods encompass covalent photoimmobilization, endpoint chemical coupling, plasma polymerization, and solution-based coating techniques, each optimized for substrate compatibility and mechanical durability under physiological shear stress. These technologies are integrated into a broad spectrum of devices, encompassing coronary and peripheral endovascular stents, ePTFE and polyester vascular grafts, indwelling catheters for central venous access and hemodialysis, extracorporeal membrane oxygenation circuits and cardiopulmonary bypass components, and rotary blood pumps in ventricular assist systems. Validation through ISO 10993-4 hemocompatibility testing protocols, complemented by ex vivo flow loop studies, large-animal implantation models, and clinical performance data from regulatory-approved devices, substantiates the reduction in thrombus formation and improvement in device patency and safety.

Read the full market overview

The global Hemocompatible Coatings market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Hemocompatible Coatings is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hemocompatible Coatings is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Asia-Pacific market for Hemocompatible Coatings is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hemocompatible Coatings is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Hemocompatible Coatings include Surmodics, Carmeda AB, Coatings2Go, DSM Biomedical, Hydromer, AST Products, Smart Reactors, Alfa Chemistry and Biomerics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hemocompatible Coatings, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hemocompatible Coatings, also provides the revenue of main regions and countries. Of the upcoming market potential for Hemocompatible Coatings, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hemocompatible Coatings revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hemocompatible Coatings market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hemocompatible Coatings revenue, projected growth trends, production technology, application and end-user industry.

Hemocompatible Coatings Segment by Company

Surmodics

Carmeda AB

Coatings2Go

DSM Biomedical

Hydromer

AST Products

Smart Reactors

Alfa Chemistry

Biomerics

Jiangsu Biosurf Biotech

Corline Biomedical

BioInteractions

Aurorium

Alta Biomed

jMedtech

Hemocompatible Coatings Segment by Type

Active (heparin)

Passive (non-heparin)

Hemocompatible Coatings Segment by Application

Interventional Catheters

ECMO & Extracorporeal

Stents & Vascular Grafts

Hemocompatible Coatings Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemocompatible Coatings market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemocompatible Coatings and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemocompatible Coatings.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hemocompatible Coatings in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hemocompatible Coatings company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemocompatible Coatings revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hemocompatible Coatings Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Active (heparin) Major Player Table 3. Passive (non-heparin) Major Player Table 4. Global Hemocompatible Coatings Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Interventional Catheters Major Player Table 6. ECMO & Extracorporeal Major Player Table 7. Stents & Vascular Grafts Major Player Table 8. Hemocompatible Coatings Industry Trends Table 9. Hemocompatible Coatings Industry Drivers Table 10. Hemocompatible Coatings Industry Opportunities and Challenges Table 11. Hemocompatible Coatings Industry Restraints Table 12. Global Hemocompatible Coatings Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Hemocompatible Coatings Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Hemocompatible Coatings Market Share by Region (2021-2026) Table 15. Global Hemocompatible Coatings Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Hemocompatible Coatings Market Share by Region (2027-2032) Table 17. Global Hemocompatible Coatings Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Hemocompatible Coatings Revenue Market Share by Players (2021-2026) Table 19. Global Hemocompatible Coatings Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Hemocompatible Coatings Key Players Headquarters & Area Served Table 21. Global Hemocompatible Coatings Players, Product Type & Application Table 22. Global Hemocompatible Coatings Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Hemocompatible Coatings by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Hemocompatible Coatings Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Hemocompatible Coatings Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Hemocompatible Coatings Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Hemocompatible Coatings Revenue Market Share by Type (2021-2026) Table 29. Global Hemocompatible Coatings Revenue Market Share by Type (2027-2032) Table 30. Global Hemocompatible Coatings Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Hemocompatible Coatings Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Hemocompatible Coatings Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Hemocompatible Coatings Revenue Market Share by Application (2021-2026) Table 34. Global Hemocompatible Coatings Revenue Market Share by Application (2027-2032) Table 35. Surmodics Company Information Table 36. Surmodics Business Overview Table 37. Surmodics Hemocompatible Coatings Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Surmodics Hemocompatible Coatings Product Portfolio Table 39. Surmodics Recent Development Table 40. Carmeda AB Company Information Table 41. Carmeda AB Business Overview Table 42. Carmeda AB Hemocompatible Coatings Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Carmeda AB Hemocompatible Coatings Product Portfolio Table 44. Carmeda AB Recent Development Table 45. Coatings2Go Company Information Table 46. Coatings2Go Business Overview Table 47. Coatings2Go Hemocompatible Coatings Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Coatings2Go Hemocompatible Coatings Product Portfolio Table 49. Coatings2Go Recent Development Table 50. DSM Biomedical Company Information Table 51. DSM Biomedical Business Overview Table 52. DSM Biomedical Hemocompatible Coatings Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. DSM Biomedical Hemocompatible Coatings Product Portfolio Table 54. DSM Biomedical Recent Development Table 55. Hydromer Company Information Table 56. Hydromer Business Overview Table 57. Hydromer Hemocompatible Coatings Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Hydromer Hemocompatible Coatings Product Portfolio Table 59. Hydromer Recent Development Table 60. AST Products Company Information Table 61. AST Products Business Overview Table 62. AST Products Hemocompatible Coatings Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. AST Products Hemocompatible Coatings Product Portfolio Table 64. AST Products Recent Development Table 65. Smart Reactors Company Information Table 66. Smart Reactors Business Overview Table 67. Smart Reactors Hemocompatible Coatings Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Smart Reactors Hemocompatible Coatings Product Portfolio Table 69. Smart Reactors Recent Development Table 70. Alfa Chemistry Company Information Table 71. Alfa Chemistry Business Overview Table 72. Alfa Chemistry Hemocompatible Coatings Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Alfa Chemistry Hemocompatible Coatings Product Portfolio Table 74. Alfa Chemistry Recent Development Table 75. Biomerics Company Information Table 76. Biomerics Business Overview Table 77. Biomerics Hemocompatible Coatings Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Biomerics Hemocompatible Coatings Product Portfolio Table 79. Biomerics Recent Development Table 80. Jiangsu Biosurf Biotech Company Information Table 81. Jiangsu Biosurf Biotech Business Overview Table 82. Jiangsu Biosurf Biotech Hemocompatible Coatings Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Jiangsu Biosurf Biotech Hemocompatible Coatings Product Portfolio Table 84. Jiangsu Biosurf Biotech Recent Development Table 85. Corline Biomedical Company Information Table 86. Corline Biomedical Business Overview Table 87. Corline Biomedical Hemocompatible Coatings Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Corline Biomedical Hemocompatible Coatings Product Portfolio Table 89. Corline Biomedical Recent Development Table 90. BioInteractions Company Information Table 91. BioInteractions Business Overview Table 92. BioInteractions Hemocompatible Coatings Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. BioInteractions Hemocompatible Coatings Product Portfolio Table 94. BioInteractions Recent Development Table 95. Aurorium Company Information Table 96. Aurorium Business Overview Table 97. Aurorium Hemocompatible Coatings Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Aurorium Hemocompatible Coatings Product Portfolio Table 99. Aurorium Recent Development Table 100. Alta Biomed Company Information Table 101. Alta Biomed Business Overview Table 102. Alta Biomed Hemocompatible Coatings Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Alta Biomed Hemocompatible Coatings Product Portfolio Table 104. Alta Biomed Recent Development Table 105. jMedtech Company Information Table 106. jMedtech Business Overview Table 107. jMedtech Hemocompatible Coatings Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. jMedtech Hemocompatible Coatings Product Portfolio Table 109. jMedtech Recent Development Table 110. North America Hemocompatible Coatings Revenue by Type (2021-2026) & (US$ Million) Table 111. North America Hemocompatible Coatings Revenue by Type (2027-2032) & (US$ Million) Table 112. North America Hemocompatible Coatings Revenue by Application (2021-2026) & (US$ Million) Table 113. North America Hemocompatible Coatings Revenue by Application (2027-2032) & (US$ Million) Table 114. North America Hemocompatible Coatings Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Hemocompatible Coatings Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Hemocompatible Coatings Revenue by Country (US$ Million) & (2027-2032) Table 117. Europe Hemocompatible Coatings Revenue by Type (2021-2026) & (US$ Million) Table 118. Europe Hemocompatible Coatings Revenue by Type (2027-2032) & (US$ Million) Table 119. Europe Hemocompatible Coatings Revenue by Application (2021-2026) & (US$ Million) Table 120. Europe Hemocompatible Coatings Revenue by Application (2027-2032) & (US$ Million) Table 121. Europe Hemocompatible Coatings Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Hemocompatible Coatings Revenue by Country (2021-2026) & (US$ Million) Table 123. Europe Hemocompatible Coatings Revenue by Country (US$ Million) & (2027-2032) Table 124. China Hemocompatible Coatings Revenue by Type (2021-2026) & (US$ Million) Table 125. China Hemocompatible Coatings Revenue by Type (2027-2032) & (US$ Million) Table 126. China Hemocompatible Coatings Revenue by Application (2021-2026) & (US$ Million) Table 127. China Hemocompatible Coatings Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Hemocompatible Coatings Revenue by Type (2021-2026) & (US$ Million) Table 129. Asia Hemocompatible Coatings Revenue by Type (2027-2032) & (US$ Million) Table 130. Asia Hemocompatible Coatings Revenue by Application (2021-2026) & (US$ Million) Table 131. Asia Hemocompatible Coatings Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Hemocompatible Coatings Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Hemocompatible Coatings Revenue by Region (US$ Million) & (2021-2026) Table 134. Asia Hemocompatible Coatings Revenue by Region (US$ Million) & (2027-2032) Table 135. SAMEA Hemocompatible Coatings Revenue by Type (2021-2026) & (US$ Million) Table 136. SAMEA Hemocompatible Coatings Revenue by Type (2027-2032) & (US$ Million) Table 137. SAMEA Hemocompatible Coatings Revenue by Application (2021-2026) & (US$ Million) Table 138. SAMEA Hemocompatible Coatings Revenue by Application (2027-2032) & (US$ Million) Table 139. SAMEA Hemocompatible Coatings Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. SAMEA Hemocompatible Coatings Revenue by Country (2021-2026) & (US$ Million) Table 141. SAMEA Hemocompatible Coatings Revenue by Country (US$ Million) & (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Hemocompatible Coatings Image Figure 2. Global Hemocompatible Coatings Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemocompatible Coatings Market Size Share 2021 VS 2025 VS 2032 Figure 4. Active (heparin) Image Figure 5. Passive (non-heparin) Image Figure 6. Global Hemocompatible Coatings Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Hemocompatible Coatings Market Size Share 2021 VS 2025 VS 2032 Figure 8. Interventional Catheters Image Figure 9. ECMO & Extracorporeal Image Figure 10. Stents & Vascular Grafts Image Figure 11. Global Hemocompatible Coatings Market Size (US$ Million) & (2021-2032) Figure 12. Global Hemocompatible Coatings Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Hemocompatible Coatings Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Hemocompatible Coatings Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Hemocompatible Coatings Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Hemocompatible Coatings Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Hemocompatible Coatings Revenue Market Share by Type (2021-2032) Figure 19. Global Hemocompatible Coatings Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Hemocompatible Coatings Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Hemocompatible Coatings Revenue Market Share by Application (2021-2032) Figure 22. North America Hemocompatible Coatings Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Hemocompatible Coatings Revenue Share by Type (2021-2032) Figure 24. North America Hemocompatible Coatings Revenue Share by Application (2021-2032) Figure 25. North America Hemocompatible Coatings Revenue Share by Country (2021-2032) Figure 26. United States Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Hemocompatible Coatings Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Hemocompatible Coatings Revenue Share by Type (2021-2032) Figure 31. Europe Hemocompatible Coatings Revenue Share by Application (2021-2032) Figure 32. Europe Hemocompatible Coatings Revenue Share by Country (2021-2032) Figure 33. Germany Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Hemocompatible Coatings Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Hemocompatible Coatings Revenue Share by Type (2021-2032) Figure 43. China Hemocompatible Coatings Revenue Share by Application (2021-2032) Figure 44. Asia Hemocompatible Coatings Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Hemocompatible Coatings Revenue Share by Type (2021-2032) Figure 46. Asia Hemocompatible Coatings Revenue Share by Application (2021-2032) Figure 47. Asia Hemocompatible Coatings Revenue Share by Region (2021-2032) Figure 48. Japan Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Hemocompatible Coatings Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Hemocompatible Coatings Revenue Share by Type (2021-2032) Figure 56. SAMEA Hemocompatible Coatings Revenue Share by Application (2021-2032) Figure 57. SAMEA Hemocompatible Coatings Revenue Share by Country (2021-2032) Figure 58. Brazil Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Hemocompatible Coatings Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Active (heparin)
  • Passive (non-heparin)
Applications
  • Interventional Catheters
  • ECMO & Extracorporeal
  • Stents & Vascular Grafts
Companies covered
  • Surmodics
  • Carmeda AB
  • Coatings2Go
  • DSM Biomedical
  • Hydromer
  • AST Products
  • Smart Reactors
  • Alfa Chemistry
  • Biomerics
  • Jiangsu Biosurf Biotech
  • Corline Biomedical
  • BioInteractions
  • Aurorium
  • Alta Biomed
  • jMedtech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hemocompatible Coatings Market by Type
  3. 1.2.1 Global Hemocompatible Coatings Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Active (heparin)
  5. 1.2.3 Passive (non-heparin)
  6. 1.3 Hemocompatible Coatings Market by Application
  7. 1.3.1 Global Hemocompatible Coatings Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Interventional Catheters
  9. 1.3.3 ECMO & Extracorporeal
  10. 1.3.4 Stents & Vascular Grafts
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Hemocompatible Coatings Market Dynamics
  1. 2.1 Hemocompatible Coatings Industry Trends
  2. 2.2 Hemocompatible Coatings Industry Drivers
  3. 2.3 Hemocompatible Coatings Industry Opportunities and Challenges
  4. 2.4 Hemocompatible Coatings Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hemocompatible Coatings Market Perspective (2021-2032)
  2. 3.2 Global Hemocompatible Coatings Growth Trends by Region
  3. 3.2.1 Global Hemocompatible Coatings Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hemocompatible Coatings Market Size by Region (2021-2026)
  5. 3.2.3 Global Hemocompatible Coatings Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hemocompatible Coatings Revenue by Players
  2. 4.1.1 Global Hemocompatible Coatings Revenue by Players (2021-2026)
  3. 4.1.2 Global Hemocompatible Coatings Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hemocompatible Coatings Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hemocompatible Coatings Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hemocompatible Coatings Key Players Headquarters & Area Served
  7. 4.4 Global Hemocompatible Coatings Players, Product Type & Application
  8. 4.5 Global Hemocompatible Coatings Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hemocompatible Coatings Market CR5 and HHI
  11. 4.6.3 2025 Hemocompatible Coatings Tier 1, Tier 2, and Tier 3
5 Hemocompatible Coatings Market Size by Type
  1. 5.1 Global Hemocompatible Coatings Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hemocompatible Coatings Revenue by Type (2021-2032)
  3. 5.3 Global Hemocompatible Coatings Revenue Market Share by Type (2021-2032)
6 Hemocompatible Coatings Market Size by Application
  1. 6.1 Global Hemocompatible Coatings Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hemocompatible Coatings Revenue by Application (2021-2032)
  3. 6.3 Global Hemocompatible Coatings Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Surmodics
  2. 7.1.1 Surmodics Company Information
  3. 7.1.2 Surmodics Business Overview
  4. 7.1.3 Surmodics Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Surmodics Hemocompatible Coatings Product Portfolio
  6. 7.1.5 Surmodics Recent Developments
  7. 7.2 Carmeda AB
  8. 7.2.1 Carmeda AB Company Information
  9. 7.2.2 Carmeda AB Business Overview
  10. 7.2.3 Carmeda AB Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Carmeda AB Hemocompatible Coatings Product Portfolio
  12. 7.2.5 Carmeda AB Recent Developments
  13. 7.3 Coatings2Go
  14. 7.3.1 Coatings2Go Company Information
  15. 7.3.2 Coatings2Go Business Overview
  16. 7.3.3 Coatings2Go Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Coatings2Go Hemocompatible Coatings Product Portfolio
  18. 7.3.5 Coatings2Go Recent Developments
  19. 7.4 DSM Biomedical
  20. 7.4.1 DSM Biomedical Company Information
  21. 7.4.2 DSM Biomedical Business Overview
  22. 7.4.3 DSM Biomedical Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  23. 7.4.4 DSM Biomedical Hemocompatible Coatings Product Portfolio
  24. 7.4.5 DSM Biomedical Recent Developments
  25. 7.5 Hydromer
  26. 7.5.1 Hydromer Company Information
  27. 7.5.2 Hydromer Business Overview
  28. 7.5.3 Hydromer Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Hydromer Hemocompatible Coatings Product Portfolio
  30. 7.5.5 Hydromer Recent Developments
  31. 7.6 AST Products
  32. 7.6.1 AST Products Company Information
  33. 7.6.2 AST Products Business Overview
  34. 7.6.3 AST Products Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AST Products Hemocompatible Coatings Product Portfolio
  36. 7.6.5 AST Products Recent Developments
  37. 7.7 Smart Reactors
  38. 7.7.1 Smart Reactors Company Information
  39. 7.7.2 Smart Reactors Business Overview
  40. 7.7.3 Smart Reactors Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Smart Reactors Hemocompatible Coatings Product Portfolio
  42. 7.7.5 Smart Reactors Recent Developments
  43. 7.8 Alfa Chemistry
  44. 7.8.1 Alfa Chemistry Company Information
  45. 7.8.2 Alfa Chemistry Business Overview
  46. 7.8.3 Alfa Chemistry Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Alfa Chemistry Hemocompatible Coatings Product Portfolio
  48. 7.8.5 Alfa Chemistry Recent Developments
  49. 7.9 Biomerics
  50. 7.9.1 Biomerics Company Information
  51. 7.9.2 Biomerics Business Overview
  52. 7.9.3 Biomerics Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Biomerics Hemocompatible Coatings Product Portfolio
  54. 7.9.5 Biomerics Recent Developments
  55. 7.10 Jiangsu Biosurf Biotech
  56. 7.10.1 Jiangsu Biosurf Biotech Company Information
  57. 7.10.2 Jiangsu Biosurf Biotech Business Overview
  58. 7.10.3 Jiangsu Biosurf Biotech Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Jiangsu Biosurf Biotech Hemocompatible Coatings Product Portfolio
  60. 7.10.5 Jiangsu Biosurf Biotech Recent Developments
  61. 7.11 Corline Biomedical
  62. 7.11.1 Corline Biomedical Company Information
  63. 7.11.2 Corline Biomedical Business Overview
  64. 7.11.3 Corline Biomedical Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Corline Biomedical Hemocompatible Coatings Product Portfolio
  66. 7.11.5 Corline Biomedical Recent Developments
  67. 7.12 BioInteractions
  68. 7.12.1 BioInteractions Company Information
  69. 7.12.2 BioInteractions Business Overview
  70. 7.12.3 BioInteractions Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  71. 7.12.4 BioInteractions Hemocompatible Coatings Product Portfolio
  72. 7.12.5 BioInteractions Recent Developments
  73. 7.13 Aurorium
  74. 7.13.1 Aurorium Company Information
  75. 7.13.2 Aurorium Business Overview
  76. 7.13.3 Aurorium Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Aurorium Hemocompatible Coatings Product Portfolio
  78. 7.13.5 Aurorium Recent Developments
  79. 7.14 Alta Biomed
  80. 7.14.1 Alta Biomed Company Information
  81. 7.14.2 Alta Biomed Business Overview
  82. 7.14.3 Alta Biomed Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Alta Biomed Hemocompatible Coatings Product Portfolio
  84. 7.14.5 Alta Biomed Recent Developments
  85. 7.15 jMedtech
  86. 7.15.1 jMedtech Company Information
  87. 7.15.2 jMedtech Business Overview
  88. 7.15.3 jMedtech Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  89. 7.15.4 jMedtech Hemocompatible Coatings Product Portfolio
  90. 7.15.5 jMedtech Recent Developments
8 North America
  1. 8.1 North America Hemocompatible Coatings Revenue (2021-2032)
  2. 8.2 North America Hemocompatible Coatings Revenue by Type (2021-2032)
  3. 8.2.1 North America Hemocompatible Coatings Revenue by Type (2021-2026)
  4. 8.2.2 North America Hemocompatible Coatings Revenue by Type (2027-2032)
  5. 8.3 North America Hemocompatible Coatings Revenue Share by Type (2021-2032)
  6. 8.4 North America Hemocompatible Coatings Revenue by Application (2021-2032)
  7. 8.4.1 North America Hemocompatible Coatings Revenue by Application (2021-2026)
  8. 8.4.2 North America Hemocompatible Coatings Revenue by Application (2027-2032)
  9. 8.5 North America Hemocompatible Coatings Revenue Share by Application (2021-2032)
  10. 8.6 North America Hemocompatible Coatings Revenue by Country
  11. 8.6.1 North America Hemocompatible Coatings Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hemocompatible Coatings Revenue by Country (2021-2026)
  13. 8.6.3 North America Hemocompatible Coatings Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Hemocompatible Coatings Revenue (2021-2032)
  2. 9.2 Europe Hemocompatible Coatings Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hemocompatible Coatings Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hemocompatible Coatings Revenue by Type (2027-2032)
  5. 9.3 Europe Hemocompatible Coatings Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hemocompatible Coatings Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hemocompatible Coatings Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hemocompatible Coatings Revenue by Application (2027-2032)
  9. 9.5 Europe Hemocompatible Coatings Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hemocompatible Coatings Revenue by Country
  11. 9.6.1 Europe Hemocompatible Coatings Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hemocompatible Coatings Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hemocompatible Coatings Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Hemocompatible Coatings Revenue (2021-2032)
  2. 10.2 China Hemocompatible Coatings Revenue by Type (2021-2032)
  3. 10.2.1 China Hemocompatible Coatings Revenue by Type (2021-2026)
  4. 10.2.2 China Hemocompatible Coatings Revenue by Type (2027-2032)
  5. 10.3 China Hemocompatible Coatings Revenue Share by Type (2021-2032)
  6. 10.4 China Hemocompatible Coatings Revenue by Application (2021-2032)
  7. 10.4.1 China Hemocompatible Coatings Revenue by Application (2021-2026)
  8. 10.4.2 China Hemocompatible Coatings Revenue by Application (2027-2032)
  9. 10.5 China Hemocompatible Coatings Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hemocompatible Coatings Revenue (2021-2032)
  2. 11.2 Asia Hemocompatible Coatings Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hemocompatible Coatings Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hemocompatible Coatings Revenue by Type (2027-2032)
  5. 11.3 Asia Hemocompatible Coatings Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hemocompatible Coatings Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hemocompatible Coatings Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hemocompatible Coatings Revenue by Application (2027-2032)
  9. 11.5 Asia Hemocompatible Coatings Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hemocompatible Coatings Revenue by Country
  11. 11.6.1 Asia Hemocompatible Coatings Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hemocompatible Coatings Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hemocompatible Coatings Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hemocompatible Coatings Revenue (2021-2032)
  2. 12.2 SAMEA Hemocompatible Coatings Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hemocompatible Coatings Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hemocompatible Coatings Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hemocompatible Coatings Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hemocompatible Coatings Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hemocompatible Coatings Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hemocompatible Coatings Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hemocompatible Coatings Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hemocompatible Coatings Revenue by Country
  11. 12.6.1 SAMEA Hemocompatible Coatings Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hemocompatible Coatings Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hemocompatible Coatings Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst